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The time to reperfusion with E601 0 was shorter than that with native t-PA.
Coronary recanalization at 30 and 60 minutes after administration was ob-
tained in 61.9% and 79.4% of the case with E6010 and in 32.4% and 64.7%
of the case with native t-PA, and the difference between both were statisti-
cally significant. No fatal bleeding complications were observed in E601 O. 4
patients (3.8%1 in E6010 and 3 patients (2.8%) in native t-PA died during 48
days post treatment hospitalization.
Discussion and Conclusion: Native t-PA is required to be administered over
period of 1 hr with 10% of the total dose administered as an i.v. bolus and the
remainder infused i.v. over 1 hr. Our present results indicate that E601 0 can
be easily administered by i.v. bolus injection taking 2-3 minutes and it exerts
a valuable thrombolytic effects, namely a high rate and early recanalization
of infarct-related arteries.
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E6010 is a novel modified t-PA, in which cysteine 84 in the epidermal growth
factor domain has been replaced by serine. This is the first modified t-PA to
be effective by i.v. bolus injection, and it has a prolonged half-life (Ta1/2 >
20 min) compared to native t-PA.
A randomized, double-blind multicenter trial of Lv. bolus injection of E601 0,
27,500 EU/kg, compared with native t-PA (cell culture). 14.400,000 IU has
been performed in the treatment of AMI of ~6 hr duration and total occlu-
sion of the infarct-related arteries. Angiograms were used to evaluate the
patency of infarct-related arteries at 15, 30, 45, and 60 minutes after the ad-
ministration. Result:
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Few data exist regarding the need for noninvasive testing after reperfusion
therapy in myocardial patients at low clinical risk. Moreover, after thromboly-
sis, recurrent ischemia occurs frequently and unpredictably and has resulted
in physician reluctance to shorten the length of hospitalization in these pa-
tients. Alternatively, emergency catheterization with primary PTCA may pro-
vide acute determination of risk status, a stable method of reperfusion and
the potential for early discharge. The objective of this multicenter study was
to prospectively test the hypothesis that early discharge (day 31 without non-
invasive risk stratification in low risk MI patients treated with primary angio-
plasty is safe, feasible, and cost effective. Patients with acute myocardial
infarction 0-12 hrs who had an emergency catheterization and immediate
PTCA of the infarct related artery were stratified into a low risk group if age
~70 yrs, 1 or 2 vessel disease, EF > 45%, successful infarct vessel PTCA and
no malignant arrhythmias persisted after the PTCA. Low risk patients were
randomized to admission to either the intenSive care unit (with hospitaliza-
tion a minimum of 5 days and predischarge exercise testing) or admission
to a non-intensive care PTCA unit with no non-'Invasive testing and discharge
on day 3. To date, 340 of the anticipated 400 patients have been enrolled.
The mean age was 56 ± 9, estimated ejection fraction 56 ± 9 and 74% had
single vessel disease. As expected, in-hospital complications occurred infre-
quently; death 1.1 %, recurrent MI 1.7%; stroke 0.6%; heart failure 4.6%.
At 1 week follow-up, no complications attributed to early discharge have
occurred. Thus, acute catheterization does allow identification of low risk MI
patients who can be safely admitted to an elective PTCA unit and discharged
in 3 days without additional testing. Complete data on the 400 patient cohort
including cost and 6 week follow-up will be available by March 1995
To evaluate the role of immediate intravenous (IV) fJ blockade in patients
treated with thrombolytic agents and aspirin for acute myocardial infarction,
we compared the outcome in the group of patients enrolled in the GUSTO
trial who received atenolol IV followed by oral dose (gr.A, n = 16406) with
